BioNTech Clocks Over $6B In Q1 Sales, Sticks To FY22 Guidance

  • BioNTech SE BNTX has reported Q1 FY22 revenues of €6.37 billion compared to €2.05 billion a year ago, mainly due to high demand for the company's COVID-19 vaccine.
  • In Q1 FY22, BioNTech and its partner Pfizer Inc PFE have invoiced approximately 750 million COVID-19 vaccine doses.
  • As of end-April 2022, the companies have signed orders for approximately 2.4 billion doses in 2022 and are on track to deliver more than 2 billion doses of COVID-19 vaccine to low- and middle-income countries by the end of 2022.
  • BioNTech generated an operating income of €4.75 billion, compared to €1.67 billion a year ago. 
  • Net profit more than doubled to €3.69 billion versus €1.13 billion. Cash and cash equivalents stood at €6.16 billion.
  • Outlook: BioNTech reaffirms FY22 COVID-19 vaccine revenues of €13 billion - €17 billion.
  • Price Action: BNTX shares are trading 0.99% higher at $137.52 during the premarket session on Monday's last check.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: BiotechEarningsLarge CapNewsGuidanceHealth CareGeneralBriefsCOVID-19 CoronavirusCOVID-19 Vaccine
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!